Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment

ConclusionACL/FF 400/12  µg was a cost-saving therapy in patients with moderate-to-severe COPD in Spain, and provided equivalent effects compared to TIO/OLO 5/5 µg.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research